Zura Bio (NASDAQ:ZURA) and MiNK Therapeutics (NASDAQ:INKT) Head-To-Head Analysis

Zura Bio (NASDAQ:ZURA) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Volatility and Risk

Zura Bio has a beta of 0.03, suggesting that its stock price is 97% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.

Insider and Institutional Ownership

61.1% of Zura Bio shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 12.4% of Zura Bio shares are held by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Zura Bio and MiNK Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35 million	($1.09)	-3.23
MiNK Therapeutics	N/A	N/A	-$12.49 million	($2.84)	-4.16

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Zura Bio and MiNK Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
MiNK Therapeutics	N/A	N/A	-118.57%

Analyst Ratings

This is a breakdown of current ratings and target prices for Zura Bio and MiNK Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1	1	3	1	2.67
MiNK Therapeutics	1	2	1	1	2.40

Zura Bio currently has a consensus price target of $10.75, suggesting a potential upside of 205.40%. MiNK Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 196.36%. Given Zura Bio’s stronger consensus rating and higher probable upside, research analysts plainly believe Zura Bio is more favorable than MiNK Therapeutics.

Summary

Zura Bio beats MiNK Therapeutics on 7 of the 11 factors compared between the two stocks.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.